Description
Founded in 2010, Boehringer Ingelheim Venture Fund is a venture capital based in Ingelheim am Rhein, Germany. The seeks prefers to invest in companies operating in the healthcare sector.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
---|---|---|---|---|---|---|
Rewind Therapeutics | 25-Jan-2023 | Later Stage VC | Drug Discovery | Generating Revenue | 000000000 00000 00.0 | |
000000 00000000000 | 29-Nov-2022 | 00000 00000 | 0000 | Drug Discovery | Generating Revenue | 000 0000 00.0 |
00000000 | 03-Nov-2022 | 00000 00000 | 0000 | Biotechnology | Pre-Clinical Trials | 000 00 00.0 |
0000000000 | 15-Sep-2022 | 00000 00000 | 0000 | Decision/Risk Analysis | Generating Revenue | |
0-00 0000000 00000 | 01-Sep-2022 | 0000 00000 | 00.000 | Monitoring Equipment | Generating Revenue | 000000000 000000 |
000000 00000000000 | 13-Jul-2022 | 00000 00000 | 00000 | Drug Discovery | Pre-Clinical Trials | |
0000000 0000000000 | 10-Jun-2022 | 00000 00000 | 00000 | Drug Discovery | Clinical Trials - Phase 2 | |
00000000 | 03-Mar-2022 | 0000 00000 | 0000 | Drug Discovery | Startup | 000 0000 00.0 |
Centauri Therapeutics | 26-Jan-2022 | Later Stage VC | 000.00 | Drug Discovery | Generating Revenue | 00000000 000000000 00.0 |
Brainomix | 16-Dec-2021 | Later Stage VC | 000.00 | Diagnostic Equipment | Generating Revenue | 000000 00000 |
Company Name | Exit Date | Exit Type | Exit Size |
---|---|---|---|
Anagenesis Biotechnologies | 05-Dec-2022 | Bankruptcy: Liquidation | |
0000000 0000000000 | 01-Jul-2022 | 000 00 00000000 | |
000000 000000000 | 21-Sep-2021 | 000000000000000000 | |
000 000000000000 | 01-Dec-2020 | 000000000000000000 | 00.00 |
0000000 | 20-Apr-2020 | 000000000000000000 | |
0000 000000000000 | 15-Jul-2019 | 000000000000000000 | 00000 |
00000 000000000000 | 01-Jun-2019 | 000000000000000000 | 00000 |
0000000 000000 | 18-Apr-2019 | 000 | 0000 |
ICD Therapeutics | 29-Mar-2019 | Merger/Acquisition | |
ViraTherapeutics | 13-Sep-2018 | Merger/Acquisition | 00000 |
Name | Title | Deals | Funds | Boards | Office |
---|---|---|---|---|---|
Fei Shen Ph.D | Managing Director, USA | 0 | 0 | 0 | Ingelheim am Rhein, Germany |
Frank Kalkbrenner Ph.D | Global Head, Director & Investment Manager | 00 | 0 | 0 | Ingelheim am Rhein, Germany |
Markus Barner | Executive | Ingelheim am Rhein, Germany | |||
Oliver Reuss | Executive Director & Investment Manager | 0 | 0 | 0 | Ingelheim am Rhein, Germany |
Philipp Mueller Ph.D | Executive Director & Investment Manager | 0 | 0 | Ingelheim am Rhein, Germany |
Name | With | Exits | Lead Partner | Series | Industry |
---|---|---|---|---|---|
High-Tech Gründerfonds | 5 | 0 |
![]() |
![]() |
|
Korea Investment Partners | 0 | 0 | 0 |
![]() |
![]() |
Andera Partners | 0 | 0 |
![]() |
![]() |
|
Evotec | 0 | 0 |
![]() |
![]() |
|
Novo Holdings | 0 | 0 |
![]() |
![]() |